SCHEMBL241305

SCHEMBL241305

Nc1ccccc1N(Br)Br

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.47
ALOX15 P16050 2/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TSHR P16473 6/20 0.41
ALDH1A1 P00352 5/20 0.41
TDP1 Q9NUW8 3/20 0.41
HSD17B10 Q99714 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
HPGD P15428 2/20 0.41
CHEK1 O14757 1/20 0.38
NEK2 P51955 1/20 0.38
LIMK1 P53667 1/20 0.38
DYRK1A Q13627 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
GAA P10253 3/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5154389 0.78 CYP3A4 (0.47) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL11238026 0.77 CYP3A4 (0.53) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL5146946 0.74 CYP3A4 (0.50) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL1774407 0.74 CYP3A4 (0.50) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL7517260 0.72 CYP3A4 (0.47) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL113870 0.72 CHEK1 (0.60) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL16931972 0.72 CYP3A4 (0.47) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL15268120 0.72 CHEK1 (0.48) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL7550030 0.72 CYP3A4 (0.47) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL29707613 0.72 CHEK1 (0.60) CYP3A4ALOX15CASP1CASP7SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114874418-B Conjugated polymer based on trifluoromethyl substituted quinoxaline, and preparation method and application thereof 广东聚石科技研究有限公司 2023-12-19 CN claimed
CN-114874418-A Conjugated polymer based on trifluoromethyl substituted quinoxaline and preparation method and application thereof 广东聚石科技研究有限公司 2022-08-09 CN claimed
CN-114874418-B Conjugated polymer based on trifluoromethyl substituted quinoxaline, and preparation method and application thereof 广东聚石科技研究有限公司 2023-12-19 CN disclosed
US-11446294-B2 Non-platinum-based anti-cancer compounds for use in targeted chemotherapy LU QING BIN (CA) 2022-09-20 US disclosed
CN-114874418-A Conjugated polymer based on trifluoromethyl substituted quinoxaline and preparation method and application thereof 广东聚石科技研究有限公司 2022-08-09 CN disclosed
EP-3578176-A1 NON-PLATINUM-BASED ANTI-CANCER COMPOUNDS FOR USE IN TARGETED CHEMOTHERAPY Lu, Qing-Bin (CA) 2019-12-11 EP disclosed
EP-2935215-B1 RADIOSENSITIZER COMPOUNDS FOR USE IN COMBINATION WITH RADIATION LU QING BIN (CA) 2019-11-13 EP disclosed
EP-3055287-B1 NON-PLATINUM-BASED ANTI-CANCER COMPOUNDS FOR USE IN TARGETED CHEMOTHERAPY LU QING BIN (CA) 2019-11-06 EP disclosed
US-10463662-B2 Non-platinum-based anti-cancer compounds for use in targeted chemotherapy LU QING BIN (CA) 2019-11-05 US disclosed
US-9655965-B2 Radiosensitizer compounds for use in combination with radiation Lu qing-bin (CA) 2017-05-23 US disclosed
US-20160235743-A1 NON-PLATINUM-BASED ANTI-CANCER COMPOUNDS FOR USE IN TARGETED CHEMOTHERAPY Lu qing-bin (CA) 2016-08-18 US disclosed
US-20150343059-A1 RADIOSENSITIZER COMPOUNDS FOR USE IN COMBINATION WITH RADIATION Lu qing-bin (CA) 2015-12-03 US disclosed
EP-2935215-A1 RADIOSENSITIZER COMPOUNDS FOR USE IN COMBINATION WITH RADIATION Lu, Qing-Bin (CA) 2015-10-28 EP disclosed
WO-2015051458-A1 NON-PLATIMUN-BASED ANTI-CANCER COMPOUNDS FOR USE IN TARGETED CHEMOTHERAPY Lu qing-bin (CA) 2015-04-16 WO disclosed
WO-2014094178-A1 RADIOSENSITIZER COMPOUNDS FOR USE IN COMBINATION WITH RADIATION Lu qing-bin (CA) 2014-06-26 WO disclosed
US-20120101243-A1 SUBSTITUTED BENZAZOLOPORPHYRAZINES FOR POLYMERIZATION AND SURFACE ATTACHMENT AND ARTICLES FORMED THEREFROM UNITED STATES DEPARTMENT OF ENERGY 2012-04-26 US disclosed
US-8106393-B2 Substituted benzazoloporphyrazines for polymerization and surface attachment and articles formed therefrom NORTH CAROLINA STATE UNIVERSITY (US) 2012-01-31 US disclosed
US-20120004384-A1 SUBSTITUTED BENZAZOLOPORPHYRAZINES FOR POLYMERIZATION AND SURFACE ATTACHMENT AND ARTICLES FORMED THEREFROM UNITED STATES DEPARTMENT OF ENERGY 2012-01-05 US disclosed
US-7919770-B2 Substituted benzazoloporphyrazines for polymerization and surface attachment and articles formed therefrom NORTH CAROLINA STATE UNIVERSITY (US) 2011-04-05 US disclosed
US-20110015388-A1 Substituted benzazoloporphyrazines for polymerization and surface attachment and articles formed therefrom UNITED STATES DEPARTMENT OF ENERGY 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10463662-B2 Non-platinum-based anti-cancer compounds for use in targeted chemotherapy TOP2B, POLR2B, RB1 CYP3A4 2840/4885ALOX15 4660/4885CASP1 1806/4885
US-20150343059-A1 RADIOSENSITIZER COMPOUNDS FOR USE IN COMBINATION WITH RADIATION RB1, ERCC2, RBBP7 CYP3A4 2671/4885ALOX15 4579/4885CASP1 3330/4885
US-20120004384-A1 SUBSTITUTED BENZAZOLOPORPHYRAZINES FOR POLYMERIZATION AND SURFACE ATTACHMENT AND ARTICLES FORMED THEREFROM PNMT, HNMT, COMT CYP3A4 164/4885ALOX15 1835/4885CASP1 4062/4885
US-11446294-B2 Non-platinum-based anti-cancer compounds for use in targeted chemotherapy TOP2B, RB1, POLR2B CYP3A4 2815/4885ALOX15 4611/4885CASP1 1928/4885
US-20160235743-A1 NON-PLATINUM-BASED ANTI-CANCER COMPOUNDS FOR USE IN TARGETED CHEMOTHERAPY TOP2B, POLR2B, RB1 CYP3A4 2840/4885ALOX15 4660/4885CASP1 1806/4885
US-20120101243-A1 SUBSTITUTED BENZAZOLOPORPHYRAZINES FOR POLYMERIZATION AND SURFACE ATTACHMENT AND ARTICLES FORMED THEREFROM PNMT, HNMT, COMT CYP3A4 164/4885ALOX15 1835/4885CASP1 4062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.